Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.50 |
| ▸ | DGAT2 | Q96PD7 | 2/20 | 0.45 |
| ▸ | ACACB | O00763 | 10/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2188537 | 0.88 | ACACB (0.45) | AOC3DGAT2ACACBOGA | |
| Hydrochloric Acid SCHEMBL2189524 | 0.86 | AOC3 (0.50) | AOC3DGAT2ACACBHRH3ADRA1A | |
| SCHEMBL2224165 | 0.83 | HRH3 (0.60) | ACACBHRH3ADRA1AOGA | |
| SCHEMBL23582526 | 0.79 | KDM4E (0.59) | AOC3OGA | |
| SCHEMBL24880446 | 0.78 | HRH3 (0.47) | AOC3DGAT2ACACBHRH3OGA | |
| SCHEMBL24880754 | 0.78 | POLB (0.56) | AOC3DGAT2ACACBHRH3ADRA1A | |
| SCHEMBL23582487 | 0.78 | HDAC6 (0.53) | AOC3OGA | |
| SCHEMBL9883424 | 0.78 | OGA (0.46) | AOC3HRH3OGA | |
| SCHEMBL9883423 | 0.78 | OGA (0.46) | AOC3OGA | |
| SCHEMBL15341333 | 0.78 | OGA (0.46) | AOC3OGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | US | disclosed |
| WO-2011083314-A1 | BENZAZEPINE DERIVATIVES FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172204-A1 | COMPOUNDS AND THEIR USE | HRH3, HRH4, HRH2 | AOC3 468/4885DGAT2 4425/4885ACACB 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.